| Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors (NCT05263050) | Fox Chase Cancer Center | 2022-01-21 |
| Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases (NCT02978404) | Centre hospitalier de l'Université de Montréal (CHUM) | 2017-06-02 |
| A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer (NCT02960906) | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | 2017-05-31 |
| Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (NCT02917772) | AIO-Studien-gGmbH | 2016-10-01 |
| Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL) (NCT02880943) | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | 2016-10-01 |
| MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma (NCT02724020) | Millennium Pharmaceuticals, Inc. | 2016-06-30 |
| Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery (NCT02535351) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2015-11-01 |
| A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer (NCT02543645) | Celldex Therapeutics | 2015-10-01 |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma (NCT02386111) | Celldex Therapeutics | 2015-05-01 |
| IMaging PAtients for Cancer Drug selecTion - Renal Cell Carcinoma (IMPACT-RCC) (NCT02228954) | Radboud University Medical Center | 2014-12-01 |
| Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib (NCT02019576) | Sunnybrook Health Sciences Centre | 2014-05-01 |
| Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy (NCT02570789) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2012-12-01 |
| A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy (NCT01693822) | Institute of Cancer Research, United Kingdom | 2012-10-01 |
| Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule (NCT01499121) | Sunnybrook Health Sciences Centre | 2012-05-01 |
| Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) (NCT01472081) | Bristol-Myers Squibb | 2012-02-09 |
| First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma (NCT01521715) | iOMEDICO AG | 2012-01-24 |